China Pharma Holdings, Inc. (CPHI) SEC filings

CPHINYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30

$0.54−0.01 (-1.43%)

Close on Nov 11, 2026Market cap $23.37MP/E –Yield –

SEC filings

40 of China Pharma's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Proxy statement	DEF 14A	Dec 22, 2026	Nov 10, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 14, 2026	SEC EDGAR
Current report	8-K	Jul 22, 2026	Jul 22, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 15, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Apr 1, 2026	SEC EDGAR
Current report	8-K	Feb 26, 2026	Mar 3, 2026	SEC EDGAR
Current report	8-K	Feb 5, 2026	Feb 10, 2026	SEC EDGAR
Current report	8-K	Dec 30, 2025	Jan 6, 2026	SEC EDGAR
Current report	8-K	Dec 22, 2025	Dec 23, 2025	SEC EDGAR
Current report	8-K	Dec 4, 2025	Dec 10, 2025	SEC EDGAR
Proxy statement	DEF 14A	Dec 30, 2025	Nov 14, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 12, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 14, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 14, 2025	SEC EDGAR
Current report	8-K	Apr 4, 2025	Apr 4, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 31, 2025	SEC EDGAR
Current report	8-K	Dec 23, 2024	Dec 26, 2024	SEC EDGAR
Current report	8-K	Dec 22, 2024	Dec 26, 2024	SEC EDGAR
Current report	8-K	Dec 12, 2024	Dec 13, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 13, 2024	SEC EDGAR
Proxy statement	DEF 14A	Dec 22, 2024	Nov 12, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 14, 2024	SEC EDGAR
Current report	8-K	May 23, 2024	May 30, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 15, 2024	SEC EDGAR
Current report	8-K	May 7, 2024	May 8, 2024	SEC EDGAR
Annual report	10-K	Dec 31, 2023	Apr 1, 2024	SEC EDGAR
Current report	8-K	Mar 27, 2024	Mar 29, 2024	SEC EDGAR
Current report	8-K	Feb 23, 2024	Feb 23, 2024	SEC EDGAR
Current report	8-K	Feb 2, 2024	Feb 8, 2024	SEC EDGAR
Current report	8-K	Dec 15, 2023	Dec 21, 2023	SEC EDGAR
Current report	8-K	Dec 15, 2023	Dec 19, 2023	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2023	Nov 13, 2023	SEC EDGAR
Proxy statement	DEF 14A	Dec 18, 2023	Nov 7, 2023	SEC EDGAR
Current report	8-K	Sep 27, 2023	Oct 3, 2023	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2023	Aug 14, 2023	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2023	May 12, 2023	SEC EDGAR
Current report	8-K	Apr 13, 2023	Apr 20, 2023	SEC EDGAR
Annual report	10-K	Dec 31, 2022	Mar 30, 2023	SEC EDGAR
Current report	8-K	Mar 27, 2023	Mar 29, 2023	SEC EDGAR
Current report	8-K	Feb 24, 2023	Feb 24, 2023	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in China Pharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Apr 15, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CPHI.

Compare: CPHI vs SXTC · CPHI vs PMHS · CPHI vs PTCHF · CPHI vs ANL · CPHI vs KYNB

Revenue growth-11.0% · median 3825.8%

Gross margin11.8% · median 33.7%

Operating margin-111.8% · median -692.4%

Net margin-114.3% · median 1834.7%

Company	Revenue	Growth
KYNB	$4.62M	-37.1%
CPHI	$3.91M	-11.0%
PMHS	$3.17M	+7688.8%
SXTC	–	–
PTCHF	–	–
ANL	–	–

Company

Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 221
Held by institutions: 0.5%
Auditor: Enrome LLP
SEC CIK: 1106644

Advertisement
300 × 250

See a number that looks wrong?